###### Strengths and limitations of this study

-   The study found that the purchase of Automated Office BP (AOBP) machines by primary care offices was followed by more accurate blood pressure (BP) measurement.

-   Offices with less accurate BP measurement (more end digit preference) rounded BP readings down.

-   These offices also had higher frequencies of adverse cardiovascular outcomes.

-   The survey of AOBP machine purchase was done only in Ontario; we infer that the purchase of an AOBP machine was associated with less end digit preference elsewhere.

Introduction {#s1}
============

High blood pressure (BP) is a leading cause of increased morbidity and early mortality in adults.[@R1] BP should be routinely measured as part of clinical encounters.[@R2] However, there are long-standing concerns about the precision and accuracy of BP measurement in practice.[@R3] There is evidence that measuring BP manually, using an aneroid or mercury column sphygmomanometer, is associated with systematic recording errors including end digit preference (EDP) and observer bias.[@R5] EDP means that the observer rounds off the last digit[@R6]; for example, BPs end in zero for up to 60% of records instead of the expected 10%.[@R7] Observer bias means that BP is adjusted towards a preferred level (rounding up or rounding down).[@R8] These issues may lead to errors in the diagnosis and treatment of hypertension.[@R9]

Automated Office BP (AOBP) measurement uses a machine to record and report the numerical values of systolic and diastolic BPs on a digital display.[@R10] Three to six recordings are done; the initial reading is discarded and the remaining readings are averaged.[@R11] Research suggests that EDP is reduced as a result of this method.[@R9] AOBP is comparable to the gold standard of 24 hours automated home BP monitoring.[@R12] Canadian and European hypertension guidelines now recommend AOBP as the preferred method for office-based measurement of BP,[@R2] but have not made a recommendation to discontinue the routine use of manual BP measurement.

There is evidence that AOBP machines are increasingly used in primary care; it has been reported that \>10 000 AOBP machines are currently in use in Canada.[@R11] In a recent Canadian survey, 43% of family physicians reported using AOBP to screen for hypertension.[@R14] However, the proportion of office BP measurements done using AOBP when machines are available in an office is not known. Changes in the proportion of BPs with EDP could serve as a marker of increasing use of AOBP in primary care practice, although this requires validation.

Accurate measurement is essential for BP control. There is a need to quantify systematic BP measurement errors in primary care, consider these in the context of changing AOBP use and estimate the effects of errors on cardiovascular outcomes affected by BP control.

The objectives of this study were therefore to (1) report the EDP levels with respect to patient-level and provider-level characteristics, (2) examine the changes in EDP with AOBP uptake in offices, (3) quantify prevalence and trends in systematic recording errors in BP recording and (4) determine associations between EDP and cardiovascular outcomes.

Methods {#s2}
=======

We used a repeated cross-sectional observational design. We applied the STrengthening the Reporting of OBservational studies in Epidemiology checklist for reporting observational studies.[@R15]

Settings and data sources {#s2a}
-------------------------

### Canada {#s2a1}

The Canadian Primary Care Sentinel Surveillance Network (CPCSSN) database was used for this study.[@R16] CPCSSN is Canada's largest electronic medical record (EMR)-based chronic disease surveillance system[@R16] and includes data collected from 11 primary care practice-based research networks in 8 of Canada's 13 provinces and territories. Consenting family physicians and other primary care providers participating in CPCSSN contribute de-identified EMR data to regional network repositories; patients can opt-out if they choose to do so. Data from all participating networks are collected every 6 months and aggregated in a single central database.[@R16] The distribution of the CPCSSN patient population is reasonably similar to that of Canadian census.[@R17]

We used EMR data extracted and processed using procedures previously described.[@R16] CPCSSN case definition algorithms have been validated against chart audits for eight chronic conditions (diabetes, hypertension, chronic obstructive pulmonary disease, depression, osteoarthritis, dementia, parkinsonism and epilepsy) in multiple sites across Canada.[@R18]

### UK {#s2a2}

We repeated the analyses using the Royal College of General Practitioners (RCGP) Research and Surveillance Centre (RSC) database for the UK. This is one of Europe's oldest primary care sentinel networks.[@R6] It has been reported that the RCGP RSC has data of high quality for chronic disease, including diabetes[@R6] and cardiovascular outcomes.[@R19]

The RCGP RSC data are extracted twice weekly from the EMRs of \>150 representative general practices (groups of physicians practising in the same location) in England, covering a population of over 1.5 million patients and 3% of the population. A comparison of RCGP RSC practices with national pay-for-performance data, prescribing data and the quality and outcomes framework suggests that data are representative of the national population in terms of age and gender of the population, ethnicity and deprivation.[@R6] RCGP RSC includes comprehensive recording of cardiovascular risk factors and outcomes.[@R20]

Study population {#s2b}
----------------

We used routinely collected clinical EMR data from primary care clinics across Canada and the UK. These data were extracted in Canada as of 30 June 2016 and in the UK as of 31 December 2016. We examined BP measurements taken between 1 January 2006 and 31 December 2015 in the CPCSSN database and in the RCGP RSC database. We included all patients who were at least 18 years of age as of BP measurement date. We identified patient characteristics that may influence BP and its measurement. Patient variables included: age, sex, presence of hypertension and/or diabetes, body mass index (BMI), use of hypertensive medications. We recorded the total number of patients included for each site; a site was a group of physicians practising in the same location.

Statistical analysis {#s2c}
--------------------

We examined the proportions of BPs ending in each digit in Canada and UK. We used the entire collection of BP records in both databases to estimate the unadjusted frequency of last digit zero for both systolic and diastolic BPs with respect to patient, site and temporal characteristics.

Since many patients had BP recorded multiple times with irregular visit to primary care between January 2006 and December 2015, we chose to discard excess information using a sampling mechanism.[@R21] In particular, we generated 1000 independent replicates using the stratified sampling without replacement where one BP measurement was randomly chosen for a given patient. Logistic regression was performed on 1000 independently sampled replicates of the CPCSSN and RCGP RSC database. The ORs were estimated using the mean and 95% CIs were estimated using the 2.5% and 97.5% percentiles of 1000 bootstrap estimates.[@R22] All covariates in the regression model were held constant to their latest value for each patient with respect to the study follow-up. For example, the most recent information on BMI or the diagnosis of diabetes or hypertension medication was used for each patient. We adjusted for patient variables that may influence BP or its measurement: age, sex, presence of hypertension and/or diabetes, BMI, use of hypertensive medications. We also adjusted for the size of the practice panels, as this may influence quality of care. Finally, we adjusted for year of measurement as EDP levels changed over time.

To correlate rates of EDP with AOBP uptake, we conducted a subgroup analysis using data from the University of Toronto Practice-Based Research Network (UTOPIAN). UTOPIAN is the largest network in CPCSSN, with about 25% of data in the national database; it includes providers and patients from Toronto and surrounding areas in southern Ontario, Canada. We collected data on AOBP use from UTOPIAN practices using a survey, shown in online [supplementary material](#SP1){ref-type="supplementary-material"}. We contacted office representatives through email/phone and asked them whether there was an AOBP in the office and when it was purchased. Office representatives were also asked to estimate how often BPs were done with the machine in the past year.
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Responses were linked with EMR-based BP measurements for each site and the linked data were used for the subgroup analysis. We examined the association between length of time the machine was present in the office and the rate of EDP, as well as association between EDP for 2015 and the self-reported level of use in the past year.

We implemented unsupervised cluster analysis to categorise primary care sites into three groups for each year.[@R23] The three groups were labelled as: (1) high EDP, (2) medium EDP and (3) low or no EDP. Practices were clustered by presence of less commonly recorded end digits (1, 3, 7, 9) for both systolic BP and diastolic BP; 40% of BPs would be expected to end in one of those digits. To control for excessive noise in the data, we chose to exclude the sites with \<1000 BP measurements within a year.

Since the changes in uncommon end digits (1, 3, 7, 9) may be confounded by the recruitment of new sites over time or changes in patient populations within sites, the proportion of recording uncommon digits was reported for each measurement year, giving a rate of EDP per site per year. The similarity between all pairs belonging to the same cluster was computed using the Ward score.[@R24] We examined the mean systolic BP among patients with and without hypertension and diabetes using the classification obtained from the cluster analysis.

We estimated the annual frequency of three cardiovascular events (myocardial infarction, angina, stroke) using UK data; these conditions have not yet been validated in the Canadian data in CPCSSN. We compared sites with high EDP in each year against sites with low or no EDP for the same year. The denominator was defined as the total number of patients who had at least one BP recorded within each year of interest for each group. The numerator was defined as the total number of patients included in the denominator with a cardiovascular event within the same year. Patients with a cardiovascular event were censored in subsequent years. We estimated the standardised morbidity ratio for each condition in groups with high EDP compared with groups with low or no EDP.

The study received a favourable opinion from the RCGP RSC study review panel. CPCSSN has received REB approval from Health Canada, and each host university for all participating practice-based research networks. All participating primary care providers have provided written informed consent for the collection and analysis of their EMR data. All statistical analyses were conducted using SAS software, V.9.4 M4 (SAS Institute).

Patient and public involvement {#s2d}
------------------------------

No patients were involved in setting the research question or the outcome measures, nor were they involved in developing plans for design or implementation of the study. We received input into the study from patient and public representatives who commented on the relevance of the question and the potential impact of the research on outcomes.

Results {#s3}
=======

Data from 181 sites and 707 227 patients in CPCSSN were included; there were 5.5 million BP records. Data from 164 sites and 1 558 471 patients in the RCGP RSC database were included; there were 13.4 million BP records. Each patient was counted once, regardless of the number of BPs and number of years in which they had a BP recorded. The most frequently recorded end digit was zero while the least frequent end digits were 1, 3, 7 and 9 ([table 1](#T1){ref-type="table"}, [figure 1](#F1){ref-type="fig"}).

![Histogram of systolic (sBP) and diastolic blood pressure (dBP) in Canada and the UK.](bmjopen-2018-024970f01){#F1}

###### 

Frequency of end digits for systolic and diastolic blood pressures

  End digits   Canada   UK            
  ------------ -------- ------ ------ ------
  0            32.4     35.9   33.8   34.0
  1            3.6      3.7    4.5    4.5
  2            13.1     10.9   10.3   9.6
  3            3.8      3.8    4.8    4.7
  4            10.4     10.0   9.1    9.3
  5            7.2      6.8    8.3    8.2
  6            9.3      8.9    8.5    8.4
  7            3.9      3.8    4.9    4.8
  8            12.6     12.4   11.2   11.6
  9            3.8      3.4    4.8    4.9

Patient and site characteristics and trends in levels of EDP are shown in [table 2](#T2){ref-type="table"}. The frequency of last digit zero for both systolic and diastolic BP decreased by 11.2% in Canada and by 6.9% in the UK from 2006 to 2015. [Table 3](#T3){ref-type="table"} describes the adjusted ORs of recording zero as the last digit of systolic and diastolic BP. The ORs of last digit zero were greater among female patients (CPCSSN: OR=1.10, 95% CI 1.09 to 1.11; RCGP: OR=1.16, 95% CI 1.15 to 1.16). Patients with hypertension were less likely to have EDP than patients without hypertension (CPCSSN: OR=0.89, 95% CI 0.88 to 0.91; RCGP RSC: OR=0.79, 95% CI 0.78 to 0.80). Patients with diabetes were less likely to have EDP in Canada (OR=0.98, 95% CI 0.96 to 0.99) but were more likely to have this in the UK (OR=1.025, 95% CI 1.01 to 1.04). ORs of EDP decreased as BMI levels increased in Canada but not in the UK.

###### 

Patient/site characteristics and BP measurements ending in zero for both systolic BP and diastolic BP in Canada (CPCSSN) and the UK (RCGP RSC database)

  Characteristics                    Canada           UK                                                                            
  ---------------------------------- ---------------- ------------------ ------------------- ------------------ ------------------- -------------------
  Total                              707 227          5 503 663          1 044 031 (19.0%)   1 558 471          13 424 678          2 674 497 (19.9%)
  Age (years)                                                                                                                       
   18--39                            189 254 (26.8)   816 136 (14.8)     165 025 (20.2)      531 632 (34.1)     2 330 344 (17.4)    538 786 (23.1)
   40--59                            247 771 (35)     1 534 126 (27.9)   292 435 (19.1)      498 272 (32.0)     3 298 174 (24.6)    631 260 (19.1)
   60--79                            201 364 (28.5)   2 115 655 (38.4)   377 724 (17.9)      352 483 (22.6)     4 879 583 (36.3)    868 894 (17.8)
   80+                               68 838 (9.7)     1 037 716 (18.9)   208 847 (20.1)      176 084 (11.3)     2 916 577 (21.7)    635 557 (21.8)
  Sex                                                                                                                               
   Female                            414 644 (58.6)   3 325 256 (60.4)   648 357 (19.5)      901 866 (57.9)     8 133 678 (60.6)    1 708 742 (21.0)
   Male                              292 583 (41.4)   2 178 377 (39.6)   395 674 (18.2)      656 605 (42.13)    5 291 000 (39.4)    965 755 (18.3)
  BMI range                                                                                                                         
   Underweight (BMI\<18.5)           10 233 (1.4)     70 776 (1.3)       14 649 (20.7)       44 654 (2.9)       308 481 (2.3)       71 234 (23.1)
   Normal weight (18.5--24.9)        170 684 (24.1)   1 177 970 (21.4)   236 883 (20.1)      560 214 (36.0)     4 071 114 (30.3)    852 192 (20.9)
   Overweight (25--29.9)             182 141 (25.8)   1 545 777 (28.1)   283 163 (18.3)      446 850 (28.7)     4 412 326 (32.9)    842 338 (19.1)
   Obesity class I (30--34.9)        101 980 (14.4)   1 013 286 (18.4)   175 781 (17.3)      200 761 (12.9)     2 421 241 (18.0)    455 572 (18.8)
   Obesity class II (35--39.9)       42 235 (6.0)     468 239 (8.5)      77 408 (16.5)       71 450 (4.6)       928 259 (6.9)       176 969 (19.1)
   Obesity class III ([\>]{.ul}40)   27 451 (3.9)     320 682 (5.8)      52 327 (16.3)       37 370 (2.4)       491 533 (3.7)       96 589 (19.7)
   Not available                     172 503 (24.4)   906 903 (16.5)     203 820 (22.5)      197 172 (12.7)     791 724 (5.9)       179 603 (22.7)
  Diabetes                                                                                                                          
   Yes                               86 103 (12.2)    1 299 693 (23.6)   233 944 (18)        65 335 (4.2)       1 909 804 (14.2)    359 324 (18.8)
   No                                621 124 (87.8)   4 203 940 (76.4)   810 087 (19.3)      1 493 136 (95.1)   11 514 874 (85.8)   2 315 173 (20.1)
  Hypertension                                                                                                                      
   Yes                               185 508 (26.2)   2 704 921 (49.1)   486 787 (18)        235 716 (15.1)     6 359 131 (47.4)    1 141 665 (18.0)
   No                                521 719 (73.8)   2 798 712 (50.9)   557 244 (19.9)      1 322 755 (84.9)   7 065 547 (52.6)    1 532 832 (21.7)
  Hypertension medications                                                                                                          
   Yes                               125 484 (17.7)   2 704 947 (49.1)   395 371 (17.7)      466 800 (30.0)     8 327 009 (62.0)    1 571 464 (18.9)
   No                                581 743 (82.3)   2 798 686 (50.9)   648 660 (19.8)      1 091 671 (70.1)   5 097 669 (38.0)    1 103 033 (21.6)
  Practice site size                                                                                                                
   First quartile (smallest site)    36 363 (5.1)     249 957 (4.5)      63 781 (25.5)       173 610 (11.1)     1 671 387 (12.5)    303 084 (18.1)
   Second quartile                   77 776 (11)      584 575 (10.6)     110 411 (18.9)      305 460 (19.6)     2 836 288 (21.1)    480 604 (16.9)
   Third quartile                    156 601 (22.1)   1 156 892 (21.0)   228 521 (19.8)      416 580 (26.7)     3 774 278 (28.1)    846 481 (22.4)
   Fourth quartile (largest site)    436 487 (61.7)   3 512 209 (63.8)   641 318 (18.3)      662 821 (42.5)     5 142 725 (38.3)    1 044 328 (20.3)
  Measurement year\*                                                                                                                
   2006                              52 168 (7.4)     121 355 (2.2)      32 335 (26.6)       542 695 (34.8)     1 347 400 (10.0)    325 843 (24.2)
   2007                              81 699 (11.6)    183 591 (3.3)      49 030 (26.7)       553 033 (35.5)     1 342 979 (10.1)    303 477 (22.6)
   2008                              125 781 (17.8)   277 858 (5.0)      72 772 (26.2)       563 222 (36.1)     1 353 092 (10.1)    288 418 (21.3)
   2009                              167 345 (23.7)   368 245 (6.7)      94 871 (25.8)       572 940 (36.8)     1 358 664 (10.1)    278 829 (20.5)
   2010                              213 250 (30.2)   531 316 (9.7)      117 612 (22.1)      580 069 (37.2)     1 340 279 (10.0)    266 242 (19.9)
   2011                              263 691 (37.3)   615 364 (11.2)     125 282 (20.4)      590 921 (37.9)     1 354 956 (10.1)    257 309 (19.0)
   2012                              299 590 (42.4)   700 903 (12.7)     128 192 (18.3)      602 642 (38.7)     1 347 042 (10.0)    249 344 (18.5)
   2013                              332 809 (47.1)   813 009 (14.8)     133 434 (16.4)      617 073 (39.6)     1 366 085 (10.2)    246 754 (18.1)
   2014                              360 180 (50.9)   894 350 (16.3)     137 181 (15.3)      612 382 (39.3)     1 325 141 (9.9)     235 377 (17.8)
   2015                              386 541 (54.7)   997 642 (18.1)     153 322 (15.4)      594 589 (38.2)     1 289 040 (9.6)     222 904 (17.3)

\*Considering repeated measurements of BP for each patient with respect to measurement year.

BP, blood pressure; BMI, body mass index (weight in kg/height in m^2^); CPCSSN, Canadian Primary Care Sentinel Surveillance Network; RCGP, Royal College of General Practitioners; RSC, Research and Surveillance Centre.

###### 

Adjusted ORs of recording zero as the last digit for both systolic and diastolic blood pressure by patient and site characteristics

  Effect                     Index group                       Reference group                  Canada   UK                                                  
  -------------------------- --------------------------------- -------------------------------- -------- ---------------- --------- ------- ---------------- ---------
  Age (years)                18--39                            80+                              1.088    1.063 to 1.112   \<0.001   0.784   0.773 to 0.795   \<0.001
                             40--59                            80+                              1.012    0.990 to 1.034   0.294     0.788   0.777 to 0.798   \<0.001
                             60--79                            80+                              0.942    0.923 to 0.963   \<0.001   0.783   0.772 to 0.794   \<0.001
  Sex                        Female                            Male                             1.100    1.089 to 1.112   \<0.001   1.156   1.148 to 1.163   \<0.001
  BMI                        Underweight (BMI\<18.5)           Obesity class III (BMI\>40)      1.316    1.267 to 1.366   \<0.001   1.047   1.019 to 1.074   0.001
                             Normal (BMI 18.5--24.9)           Obesity class III                1.226    1.192 to 1.258   \<0.001   0.960   0.939 to 0.980   \<0.001
                             Overweight (BMI 25--29.9)         Obesity class III                1.135    1.104 to 1.166   \<0.001   0.947   0.926 to 0.966   \<0.001
                             Obesity class I (BMI 30--34.9)    Obesity class III                1.065    1.036 to 1.096   \<0.001   0.953   0.932 to 0.973   \<0.001
                             Obesity class II (BMI 35--39.9)   Obesity class III                1.008    0.978 to 1.040   0.618     0.967   0.943 to 0.992   0.007
  Diabetes                   Yes                               No                               0.982    0.964 to 0.999   0.047     1.025   1.008 to 1.042   0.004
  Hypertension               Yes                               No                               0.892    0.877 to 0.908   \<0.001   0.790   0.780 to 0.799   \<0.001
  Hypertension medications   Yes                               No                               0.967    0.947 to 0.986   0.001     1.057   1.047 to 1.068   \<0.001
  Practice site size         First quartile (smallest site)    Fourth quartile (largest site)   1.950    1.908 to 1.990   \<0.001   0.816   0.809 to 0.823   \<0.001
                             Second quartile                   Fourth quartile (largest site)   1.075    1.058 to 1.094   \<0.001   0.893   0.885 to 0.900   \<0.001
                             Third quartile                    Fourth quartile (largest site)   1.087    1.074 to 1.100   \<0.001   0.891   0.883 to 0.899   \<0.001
  Measurement year           2006                              2015                             1.910    1.833 to 1.990   \<0.001   1.647   1.625 to 1.668   \<0.001
                             2007                              2015                             1.923    1.857 to 1.989   \<0.001   1.473   1.451 to 1.494   \<0.001
                             2008                              2015                             1.840    1.790 to 1.895   \<0.001   1.376   1.357 to 1.396   \<0.001
                             2009                              2015                             1.858    1.815 to 1.903   \<0.001   1.321   1.300 to 1.341   \<0.001
                             2010                              2015                             1.582    1.548 to 1.617   \<0.001   1.257   1.238 to 1.275   \<0.001
                             2011                              2015                             1.379    1.352 to 1.407   \<0.001   1.178   1.161 to 1.196   \<0.001
                             2012                              2015                             1.239    1.216 to 1.262   \<0.001   1.112   1.094 to 1.129   \<0.001
                             2013                              2015                             1.096    1.077 to 1.116   \<0.001   1.052   1.038 to 1.067   \<0.001
                             2014                              2015                             1.037    1.021 to 1.052   \<0.001   1.016   1.000 to 1.030   0.041

ORs were adjusted for patient age, sex, presence of hypertension and/or diabetes, BMI, use of hypertensive medications. ORs were also adjusted for the size of the practice panels and year of measurement.

BMI, body mass index (weight in kg/height in m^2^).

Sixty-five UTOPIAN sites were surveyed; 55 (85%) responded. Ninety-three per cent of the UTOPIAN sites reported having at least one AOBP machine in the practice; most were bought between 2007 and 2014. Even when AOBP machines were present, most offices reported still using manual measurement. There was a reduction of 9.3% (from 41.7% to 32.5%) in the proportion of systolic BPs ending in zero within 3 years of adopting the AOBP machines (95% CI −8.9% to −9.8%). Family practices who reported rarely or never using AOBP machines had higher EDP than those reporting at least some use of AOBP ([figure 2](#F2){ref-type="fig"}).

![Impact of adopting automated office blood pressure machines on end digit preference for systolic blood pressure in Toronto.](bmjopen-2018-024970f02){#F2}

As illustrated in [figure 3](#F3){ref-type="fig"}, cluster analyses were used to find the optimal decision boundaries to classify sites into high EDP, medium EDP, low or no EDP for Canada and the UK. [Table 4](#T4){ref-type="table"} provides the number and percentage of sites in each group. In 2006, there was only one Canadian site (3.6%) with low or no EDP while in the UK, 61 sites (38.4%) were in this group. Sites exhibiting high EDP decreased by 47.7% in Canada and by 15.1% in the UK from 2006 to 2015. In contrast, the proportion of sites classified as having low or no EDP increased by 22.9% in Canada and 12.8% in the UK.

![Proportions of systolic blood pressure (BP) and diastolic BP ending in 1, 3, 7 or 9 per practice site for each year of interest in Canada and the UK from 2006 to 2015. EDP, end digit preference.](bmjopen-2018-024970f03){#F3}

###### 

Number and percentage of sites in each EDP group from 2006 to 2015

  Year   Canada   UK                                                          
  ------ -------- ------ ---- ------ ---- ------ ---- ------ ---- ------ ---- ------
  2006   1        3.6    1    3.6    26   92.9   61   38.4   39   24.5   59   37.1
  2007   3        7.3    3    7.3    35   85.4   69   42.9   41   25.5   51   31.7
  2008   8        13.8   3    5.2    47   81.0   71   44.1   45   28.0   45   28.0
  2009   8        11.1   7    9.7    57   79.2   74   46.0   45   28.0   42   26.1
  2010   15       15.3   11   11.2   72   73.5   76   46.6   45   27.6   42   25.8
  2011   17       15.5   16   14.5   77   70.0   78   47.9   45   27.6   40   24.5
  2012   27       21.8   25   20.2   72   58.1   82   50.3   40   24.5   41   25.2
  2013   33       22.8   33   22.8   79   54.5   79   48.5   48   29.4   36   22.1
  2014   30       20.0   41   27.3   79   52.7   85   52.1   42   25.8   36   22.1
  2015   41       26.5   44   28.4   70   45.2   84   51.2   44   26.8   36   22.0

EDP, end digit preference.

The mean systolic BP by EDP group is shown in [table 5](#T5){ref-type="table"}. Sites with low or no EDP had a higher mean systolic BP than sites with high EDP (1.97 mm Hg in Canada; 1.76 mm Hg in the UK). When stratified by presence or absence of hypertension or diabetes, the direction was similar with differences ranging from 0.9 to 2.4 mm Hg.

###### 

Mean sBP by EDP group

                     CPCSSN database (Canada)   RCGP RSC database (UK)                                             
  ------------------ -------------------------- ------------------------ -------- ----------- ----------- -------- -------
  All patients       Low or no EDP              1 151 795                128.21   18.92       5 618 800   135.05   20.09
  High EDP           2 925 279                  126.24                   18.52    3 624 391   133.29      19.63    
                     Difference                                          1.97                             1.76     
  Hypertensive       Low or no EDP              584 082                  134.59   19.29       2 687 218   142.63   19.03
  High EDP           1 436 251                  133.51                   18.36    1 715 006   141.23      18.19    
                     Difference                                          1.08                             1.40     
  Non-hypertensive   Low or no EDP              567 713                  121.65   16.09       2 931 582   128.10   18.44
  High EDP           1 489 028                  119.23                   15.77    1 909 385   126.15      18.07    
                     Difference                                          2.42                             1.95     
  Diabetic           Low or no EDP              300 630                  131.42   18.81       823 959     138.89   18.75
  High EDP           675 920                    130.52                   18.09    515 843     136.76      17.79    
                     Difference                                          0.9                              2.13     
  Non-diabetic       Low or no EDP              851 165                  127.08   18.83       4 794 841   134.39   20.23
  High EDP           2 249 359                  124.96                   18.46    3 108 548   132.71      19.86    
                     Difference                                          2.12                             1.68     

CPCSSN, Canadian Primary Care Sentinel Surveillance Network; EDP, end digit preference; RCGP, Royal College of General Practitioners; RSC, Research and Surveillance Centre; sBP, systolic blood pressure.

As shown in [figure 4](#F4){ref-type="fig"}, we observed a higher mean frequency of myocardial infarction (0.40%, 95% CI 0.39 to 0.41), stroke (0.64%, 95% CI 0.63 to 0.65) and angina (0.42%, 95% CI 0.41 to 0.43) in sites with high EDP as compared with sites with low or no EDP: 0.34% (95% CI 0.33 to 0.35), 0.56% (95% CI 0.55 to 0.57) and 0.33% (95% CI 0.32 to 0.34), respectively. [Table 6](#T6){ref-type="table"} provides the standardised morbidity ratio; this was higher for all three conditions for sites with high EDP compared with sites with low or no EDP.

![Frequency of cardiovascular events in high end digit preference (EDP) and no or low EDP group in the UK.](bmjopen-2018-024970f04){#F4}

###### 

Standardised morbidity ratio for groups with high EDP group when compared with groups with low or no EDP

  Parameter                       Estimate   95% CI
  ------------------------------- ---------- --------------
  Angina                                     
   Standardised morbidity ratio   1.25       1.22 to 1.28
  Acute myocardial infraction                
   Standardised morbidity ratio   1.16       1.14 to 1.19
  Stroke                                     
   Standardised morbidity ratio   1.15       1.12 to 1.17

EDP, end digit preference.

Discussion {#s4}
==========

We found significant levels of systematic recording errors in BP measurement in the UK and Canada; these decreased over time. There was an association between the length of time an AOBP machine was present in an office and a decrease in EDP. Higher rates of EDP, and presumably more use of manual BP recording in those sites, appeared to be associated with rounding down of BPs and a higher frequency of adverse cardiovascular outcomes.

Our study found decreasing rates of in EDP; there have been increasingly strong guideline recommendations to switch to AOBP.[@R2] While a recent survey found that almost half of Canadian physicians reported using AOBP to screen for hypertension,[@R14] most offices in this study reported continued use of manual BP measurement for some patients even when an AOBP machine was present in the office. We found a gradual decrease in EDP associated with the length of time that AOBP has been present in the office, indicating that physicians and sites may be increasingly accustomed to its routine use for measurement.

European Guidelines recommending adoption of AOBP were associated with a large decrease in recorded BPs ending in zero in the UK, from 71.2% in 1996--1997 to 36.7% in 2005--2006.[@R26] UK studies based on the Quality Improvement in Chronic Kidney Disease trial[@R27] have shown reductions over time, presumably related to the progressive introduction of AOBP, although this assumption was not validated.[@R28] In addition, there were changes in the patterns of recording odd versus even terminal digits. Another study in China also noted decreases in EDP over time.[@R29] Implementation of AOBP in offices thus appears to be correlated with decreases in EDP.[@R3]

The use of AOBP measurement resulted in lower readings than manual BP measurement (by 5--10 mm Hg) in a randomised controlled trial (RCT); AOBP readings agreed more closely with the gold standard of 24-hour BP measurement than manual BP readings.[@R11] The introduction of AOBP should therefore be associated with a combination of lower rates of EDP (greater precision) and lower BP readings that are more consistent with the gold standard (greater accuracy). An observational study, however, found an association between higher rates of EDP and lower mean systolic BP, by 2--3 mm Hg.[@R26] A study in the UK found that the change from manual to AOBP in primary care practices resulted in lower rates of EDP but no changes in mean BP.[@R3]

We found that sites with low or no EDP (those presumably using AOBP more consistently) had a mean BP that was close to 2 mm Hg higher than those with greater rates of EDP (and presumably more use of manual BP in the practice) rather than the expected 5 mm Hg lower. Therefore, observer errors associated with manual BP may have resulted in both rounding towards zero and systematically rounding down. Rounding down was observed for patients with diabetes and hypertension as well as for those without these conditions. This could potentially lead to underdiagnosis of hypertension and undertreatment of diagnosed hypertension. While there was no clinically significant association between measurement precision and presence of BP-lowering medication (ORs close to 1), our data do not permit us to determine whether more precise measurement was associated with medication intensification through increase in dosage or addition of more medications. This could benefit from additional research.

A possible explanation for the observation of rounding down is provided by prospect theory, used in behavioural economics, which describes decisions made under conditions of uncertainty. Negative perceptions about possible risks (or risk aversion) outweigh positive perceptions about possible gains.[@R30] There may be a behavioural bias towards rounding down; this may avoid perceived risks associated with adding more medications with less emphasis on gains from cardiovascular outcome prevention.

A large cluster RCT (Cardiovascular Health Awareness Program (CHAP)) documented improved management of hypertension in communities randomised to the intervention. This consisted of more accurate AOBP-based measurement in pharmacies with forwarding of abnormal BP results to family physicians.[@R31] The CHAP intervention resulted in a significant decrease in hospitalisations due to cardiovascular disease (myocardial infarction, stroke, heart failure).[@R31] In that trial, there was an improvement in BP from a mean of 142 to 123 mm Hg when the initial pharmacy-based reading was elevated.[@R32] Systematically, more accurate measurement of BP through the use of AOBP in the community, followed by notification of the primary care provider when BP was elevated, may have resulted in more treatment of elevated BP in primary care and decreased adverse cardiovascular outcomes.

The results in this real-world observational study in two countries are plausibly consistent with those of the CHAP RCT. We found that practices with greater precision for BP measurement (less EDP) also had a lower prevalence of adverse cardiovascular outcomes for their patients. It is possible that these practices were using AOBP more often and were thus measuring BP with greater accuracy. Systematic rounding down associated with higher rates of EDP and presumably greater use of manual BP measurement by practices in this study appeared to be associated with an elevated frequency of adverse cardiovascular outcomes.

A switch to routine use of AOBP for most office-based BP measurements would require the purchase of enough machines to support the number of physicians and patients in each office, training of staff and healthcare providers and changes in offices processes to support more consistent use of AOBP. We are not aware of financial or other practice level incentives in either country promoting this change.

Limitations {#s5}
===========

The study has several strengths. We used data from routine community-based primary care. We also included a large sample of both patients and primary care providers from multiple settings across Canada and the UK, observed over a decade or more. Therefore, this study reasonably reflects current clinical practices for individuals receiving primary care in both countries.

This study has several shortcomings. This was a convenience sample of primary care practices that contributed EMR data to CPCSSN and the RCGP RSC. We surveyed practices for their use of AOBP in one network only (UTOPIAN); the survey was done at the office level rather than by physician. There may be recall bias and the actual proportion of patients whose BP was measured using an AOBP is unknown.

The study was not randomised; therefore, there may be unmeasured confounders associated with both higher incidence of cardiovascular outcomes and greater rates of EDP. These could include incentives or programmes that could lead to improved precision in BP measurement along with lower rates in cardiovascular outcomes, such as quality standards or funding. Our findings are associations rather than causation. Nonetheless, the differences between groups persisted as practices switched to lower rates of EDP over time and there is no a priori reason to expect a change in unmeasured confounders in practices switching to AOBP and lower rates of EDP.

Conclusions {#s6}
===========

In conclusion, systematic measurement errors including rounding down are associated with higher rates of EDP. It is likely that this is associated with more manual BP measurement in these primary care practices and in turn is correlated with a higher risk of adverse cardiovascular outcomes at a population level, although we cannot infer a causal relationship. Our findings suggest that the continued routine use of manual measurement of BP in primary care offices may be problematic. We recommend the use of AOBP as the standard of care for measuring and monitoring BP in medical offices.
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